Phathom Pharmaceuticals (PHAT) Stock Price, Quote, News & History

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Name

Revenue

Change

Gross

Change

EBITDA

Change

EBIT

Change

Earnings

Change

About

Sector

Health Care

Industry

Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule...

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Bulls vs Bears

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Benzinga

Benzinga

Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote, News & History

Key Statistics

Recent Phathom Pharmaceuticals Inc News

PROGuggenheim Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $25

PROPhathom Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

PROPhathom Pharmaceuticals Sees FY2026 Sales $320.000M-$345.000M vs $314.481M Est

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About

Edge Rankings

Stock Score Locked: Want to See it?

Compare

FAQ

How do I buy Phathom Pharmaceuticals (PHAT) stock?

Who are Phathom Pharmaceuticals (PHAT) competitors?

What is the forecast, or price target, for Phathom Pharmaceuticals (PHAT) stock?

What is the current price for Phathom Pharmaceuticals (PHAT)?

Does Phathom Pharmaceuticals (PHAT) pay a dividend?

When is Phathom Pharmaceuticals (NASDAQ:PHAT) reporting earnings?

Is Phathom Pharmaceuticals (PHAT) going to split?

What sector and industry does Phathom Pharmaceuticals (PHAT) operate in?

People Also Watch

Key Statistics

Recent Phathom Pharmaceuticals Inc News

PROGuggenheim Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $25

PROPhathom Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

PROPhathom Pharmaceuticals Sees FY2026 Sales $320.000M-$345.000M vs $314.481M Est

Financials

Cash Flows

Analyst Trends and Forecast

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About

Edge Rankings

Stock Score Locked: Want to See it?

Bulls vs Bears

Compare

FAQ

How do I buy Phathom Pharmaceuticals (PHAT) stock?

Who are Phathom Pharmaceuticals (PHAT) competitors?

What is the forecast, or price target, for Phathom Pharmaceuticals (PHAT) stock?

What is the current price for Phathom Pharmaceuticals (PHAT)?

Does Phathom Pharmaceuticals (PHAT) pay a dividend?

When is Phathom Pharmaceuticals (NASDAQ:PHAT) reporting earnings?

Is Phathom Pharmaceuticals (PHAT) going to split?

What sector and industry does Phathom Pharmaceuticals (PHAT) operate in?

People Also Watch

Bulls vs Bears

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $25

PRO
Phathom Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

PRO
Phathom Pharmaceuticals Sees FY2026 Sales $320.000M-$345.000M vs $314.481M Est

PRO
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $25

PRO
Phathom Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.

PRO
Phathom Pharmaceuticals Sees FY2026 Sales $320.000M-$345.000M vs $314.481M Est